Online Program Home
  My Program

All Times EDT

Abstract Details

Activity Number: 409 - Estimands in Oncology: Papers from an Industry Working Group
Type: Topic-Contributed
Date/Time: Thursday, August 12, 2021 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract #319192
Title: Treatment Switching and Estimands for Overall Survival in Oncology Clinical Trials: Issues and Controversies
Author(s): Natalia Kan-Dobrosky*
Companies: PPD Inc

An addendum of the ICH E9 guideline on Statistical Principles for Clinical Trials was released in November 2019 introducing estimand framework. The framework aims to align trial objectives and statistical analyses by requiring a precise definition of the treatment effect of interest. This definition accounts for intercurrent events such as switching to new anticancer therapies for the analysis of the overall survival (OS), the gold standard in oncology.

Traditional OS analysis in confirmatory studies uses intention-to-treat (ITT) approach comparing treatments as they were initially randomized regardless of whether treatment switching occurred (treatment-policy strategy). Regulatory authorities and other stakeholders often consider ITT results as most relevant. However, the respective estimand only yields a clinically meaningful comparison of two treatment arms if subsequent therapies are already approved and reflect clinical practice. We illustrate different scenarios where subsequent therapies are not yet approved drugs and thus do not reflect clinical practice. In such situations hypothetical strategy could be more meaningful from patient’s and prescriber’s perspective.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2021 program